Glycogen synthase kinase 3b (GSK3b) has been shown to be a crucial mediator of the intensity and direction of the innate immune system response to bacterial stimuli. This review focuses on: (i) the central role of GSK3b in the regulation of pathogen-induced inflammatory responses through the regulation of pro-and antiinflammatory cytokine production, (ii) the extensive ongoing efforts to exploit GSK3b for its therapeutic potential in the control of infectious diseases, and (iii) the increasing evidence that specific pathogens target GSK3b-related pathways for immune evasion. A better understanding of complex bacteria-GSK3b interactions is likely to lead to more effective anti-inflammatory interventions and novel targets to circumvent pathogen colonization and survival.
GSK3 action and isoforms GSK3 is a highly conserved, constitutively active, serine/ threonine (S/T) protein kinase. GSK3 was originally named after its ability to phosphorylate the key rate-limiting metabolic enzyme, glycogen synthase, which controls the final step of glycogen synthesis. However, this name does not adequately describe the diverse substrates and multiple functions now attributed to GSK3, including embryonic development, cell cycle control, cell differentiation, cell mobility, apoptosis, migration, and the focus of this review -as a central regulator of the inflammatory response to bacterial infection and other insults [1] .
In mammals, two isoforms, GSK3a and GSK3b, have been identified and each are widely expressed [2] . Sequence analysis has revealed that although these two isoforms are 98% homologous within their kinase domains and 85% homologous overall [2] , the final 76 C-terminus amino acids exhibit only 36% homology [2] . This may explain functional differences between GSK isoforms, where GSK3b deficiency is embryonic lethal in mice in a manner that cannot be compensated by GSK3a [3] .
GSK3b appears to play important roles in the host response to viral [4] , fungal [5] , and parasitic infections, including malaria [6] . However, this review will focus specifically on the significance of GSK3b in the mammalian immune response, therapeutic targeting of GSK3b during bacterial infection, and exploitation of GSK3b by pathogens.
A distinct feature of GSK3 is that it displays high activity under basal conditions. This activity is differentially regulated by tyrosine and S/T phosphorylation. Tyrosine phosphorylation (Tyr279 for GSK3a and Tyr216 for GSK3b) enhances activity, whereas N-terminal serine phosphorylation (Ser21 for GSK3a and Ser9 for GSK3b) is suppressive. Other GSK3b sites, such as ERK (extracellular signal regulated kinase)-and p38-MAPK (mitogen-activated protein kinase)-phosphorylated Thr43 and Ser389, are also reported to influence GSK3b activity in the brain and thymocytes [1] . The major GSK3b-regulating event, however, seems to be Ser9 phosphorylation. Multiple extracellular signals induce rapid Ser9 phosphorylation, resulting in a dramatic decrease in enzymatic activity, with the upstream activators phosphoinositide 3-kinase (PI3K)-Ak thymoma/protein kinase B (Akt/ PKB) being the best studied ( Figure 1 ). Early studies identified the insulin-mediated signaling pathway as an activator of PI3K and, subsequently, a phospho-inactivator of both GSK3a (Ser21) and GSK3b (Ser9) [7] . Other molecules, including growth factors, phorbol esters, amino acids, interleukin receptors, Toll-like receptors (TLRs), T cell receptors, and CD28, as well as KIT (v-kit HardyZuckerman 4 feline sarcoma viral oncogene homolog) activation, have since been shown to be involved in the phosphorylation, and thus inactivation, of GSK3 [1] .
In addition to the PI3K-Akt pathway, several other kinases, such as 90 kDa ribosomal protein S6 kinase 1 (p90RSK), serum and glucocorticoid-regulated kinase 1 (SGK1), and MAPK-p38, have also been shown to phospho-inactivate GSK3b [8] [9] [10] . Because these kinases all belong to the protein kinase A, G, and C (AGC) family, it is possible that GSK3b could also be phospho-inactivated by other members of this large kinase group which control a multitude of physiological processes.
Substrate recognition by GSK3b is well defined. The kinase has a 100-1000-fold preference for phosphorylation of substrates that are pre-primed (pre-phosphorylated) on a serine or threonine located around a five amino acid consensus sequence, Ser/Thr-X-X-X-Ser/Thr-P, where the first serine or threonine of this motif is the residue phosphorylated by GSK3b [11] . Frame et al. demonstrated by mutation of Arg96 to Ala96 that this is a crucial residue in the phosphorylation of pre-primed (pre-phosphorylated), but not non-primed substrates [12] . The GSK3b crystal structure has revealed that Tyr276/216 is also important conformationally, with phosphorylation of this residue enhancing substrate binding [13] .
GSK3b is a central mediator of the immune response to bacterial infection
The immune system recognizes and responds to bacterial challenge primarily through pattern recognition receptors (PRRs) such as TLRs, retinoic acid inducible gene I (RIG-I)-like receptors (RLRs), and nucleotide binding oligomerization domain-like receptors (NLRs). Recognition of microbeassociated molecular patterns (MAMPs) by PRRs results in the initial activation of innate immune cells with an increase in the expression of inflammatory cytokines, costimulatory molecules, and major histocompatibility complex (MHC) I and II molecules, all of which work together to promote subsequent activation of the adaptive immune response. Activation of PRRs by various microbial components results in the recruitment of different downstream signaling adaptors, which confer selectivity on the repertoire of cytokines induced. Broadly speaking, signaling pathways in innate cells can be classified as myeloid differentiation primary response 88 (MyD88)-dependent, which initiate the expression of pro-[e.g. interleukin (IL)-1b, IL-6, tumor necrosis factor (TNF), IL-12] and antiinflammatory (IL-10) cytokines, or MyD88-independent, which control the production of type I interferon through TRIF-related adaptor molecule (TRAM)-TIR-domain-containing adapter-inducing interferon-b (TRIF) [14, 15] . Although GSK3b is a central regulator of adaptive (including B cell expansion and T cell polarization and cytokine production) and innate immunity, we will focus on the role of the innate arm of defense and on the increasing evidence that GSK3b inactivation has potent therapeutic potential in the control of bacteria-driven inflammatory diseases [1, 14, 16] (Figure 2) .
It has been known for many years that phosphoinactivativation of GSK3b suppresses MyD88-dependent cytokine production. This leads to downregulation of proinflammatory cytokines, but upregulation of IL-10 production, in innate cells exposed to bacterial stimuli [14, 15, 17] . Nuclear factor-kB (NF-kB) and cAMP response elementbinding protein (CREB) represent prototypical transcription factors for proinflammatory cytokines and anti-inflammatory IL-10, respectively. Phospho-inactivation of GSK3b enhances interactions of CREB with the co-transcriptor, 
S/T-X-X-X-S/T-P

PDK2/ mTORC2
GFs α-7nAChR Figure 1 . Mediators of GSK3b phosphorylation. In its active state, GSK3b exhibits a 100-1000-fold increased efficiency in substrate specificity for pre-primed (prephosphorylated) substrates, as compared to non-primed substrates. However, multiple agonists including growth factors, insulin, a7nAchR, TLRs, TCR, cytokines, CD28, and amino acids phospho-activate PI3K, which results in the generation of PIP3 that allows for the recruitment of Akt via its pleckstrin homology domain. Full activation of Akt occurs through phosphorylation (P) at threonine (T) 308 by PDK1 and serine (S) 473 by PDK2/mTORC2. Upon activation, Akt can phosphorylate GSK3b (Ser9) resulting in GSK3b inactivation. PKC and PKA also can phospho-inactivate GSK3b. Abbreviations: Akt, Ak thymoma/protein kinase B; GF, growth factor; GSK3b; glycogen synthase kinase 3b; IFN, interferon; mTORC2, mechanistic target of rapamycin complex 2; a7nAchR, a7 nicotinic acetylcholine receptor; PDK, pyruvate dehydrogenase kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PKA, protein kinase A; PKC, protein kinase C; TCR, T cell receptor; TLR, Toll-like receptor.
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Trends in Microbiology April 2014, Vol. 22, No. 4 CREB binding protein (CBP/CREBBP), attenuating CBP binding to NF-kB [17] . Moreover, active GSK3b is able to phosphorylate directly NF-kB p65 and B cell lymphoma 3-encoded protein (BCL-3), a transcriptional coactivator of the NF-kB p50 homodimer [18, 19] . Phosphorylation of BCL-3 leads to its proteasomal degradation [18] . Thus, GSK3b facilitates NF-kB activity by targeting phospho-activation of NF-kB p65 and limits NF-kB activation via unidentified BCL-3 dependent pathways. GSK3b has also been shown to phosphorylate p105 at residues Ser903 and Ser907, stabilizing p105 by preventing its degradation in unstimulated cells [20, 21] . However, in TNF-stimulated cells, GSK3b has been found to phosphorylate p105 and prime it for subsequent degradation [20] . Therefore, GSK3b exerts dual effects on p105, either suppressing or augmenting NF-kB activity depending on the context of the signal. In addition, a recent publication has reported that deficiency of MyD88 does not influence GSK3b phosphorylation levels and that inhibition of GSK3b results in a robust increase of type I interferon (IFNb) production in vitro and in vivo [22] . Augmentation of IFNb occurs via phosphorylation of the transcription factor c-Jun and the enhancement of nuclear AP-1 (activator protein-1)-ATF2 (activating transcription factor 2) complex [22] .
Apart from the classic cytokines discussed above, other inflammatory mediators, including interleukin 1 receptor antagonist (IL-1Ra/IL1RN), chemokine (C-C motif) ligand 3 (CCL3), CCL4, and nitric oxide (NO) have been reported to be regulated by GSK3b in different contexts. For example, Rehani et al. have shown that GSK3b activity GSK3b is a central player in Wnt, a7nAChR-and PI3K-mediated anti-inflammatory signaling. Microbial pathogens and their components initiate the innate immune response through activation of multiple signaling pathways, most importantly the TLR-NF-kB axis, driving the production of multiple proinflammatory cytokines. Unphosphorylated GSK3b is an essential and controlling mediator of this inflammatory response to bacteria. Probably to prevent an overly robust response to infection, several endogenous mechanisms serve to dampen bacteria-driven inflammation. The cholinergic anti-inflammatory pathway, triggered upon a7nAChR engagement by endogenous (acetylcholine) and exogenous (e.g., nicotine) agonists, is a classic example. a7nAChR-mediated activation of PI3K leads to phospho-inactivation of GSK3b at Ser9 (through Akt and PIP3) resulting in increased activity of CREB, displacement of NF-kB p65 from the coactivator of transcription, CBP, and lowered transcriptional activity of NF-kB p65-driven proinflammatory genes. Increased chromosomal access to CREB also promotes production of anti-inflammatory IL-10. Inhibitors of TLR pathway molecules (JAK3; PI3K; Akt) that normally drive GSK3b Ser9 phosphorylation (white lines) exacerbate bacteria-driven inflammation, whereas promoters of GSK3b Ser9 phosphorylation (a7nAChR pathway) or pharmaceutical GSK3b inhibitors (e.g., SB216763) suppress proinflammatory mediators while promoting anti-inflammatory IL-10 in response to infection (red lines). Perhaps independently, activation of the canonical Wnt (Wnt/b-catenin) pathway also leads to phospho-inactivation of GSK3b and stabilization of b-catenin which suppresses inflammation by interference with NF-kB. There is much current emphasis on the development of pharmacological inhibitors of GSK3b that alter the magnitude of the inflammatory response through differentially regulating pro-and anti-inflammatory cytokines. Therefore, it is possible that we will eventually be able to up-or downregulate the intensity of the innate response to bacterial infection depending on the clinical necessity. Abbreviations: CBP, CREB binding protein; CREB, cAMP response element binding protein; IL, interleukin; JAK, Janus kinase; NF-kB, nuclear factor kB; PI3K, phosphoinositide 3-kinase; Wnt, wingless-type MMTV integration site family; for other abbreviations see Figure 1 legend. [24] . Expression of inducible nitric oxide synthase (iNOS) has been demonstrated to play an important role in the clearance of intracellular pathogens. Several findings indicate that GSK3b inhibition is also capable of attenuating production of NO by suppressing the expression of iNOS in TLR-stimulated cells [25] . GSK3b thus differentially regulates TLR-mediated production of pro-and antiinflammatory cytokines, and such studies enhance the robustness of the original proposal by Martin et al. that GSK3b in its active form acts as a positive regulator of inflammation and that manipulation of GSK3b could be employed to up-or downregulate the inflammatory response, depending on the clinical necessity [17] . Our understanding of the control of inflammation by GSK3b grows ever more complex and is likely to be context-specific. For example, Hu et al. have demonstrated synergy between IFNg and TLR2 in macrophages, increasing GSK3b activity and augmenting TNF production, while suppressing IL-10. GSK3b inhibition reversed this phenomenon [26] . Furthermore, it appears that there is crosstalk between the PI3K-Akt-GSK3b pathway, the transcription factor STAT3 (signal transducer and activator of transcription 3), and other endogenous signaling networks that control inflammation, in other words the a7 nicotinic acetylcholine receptor (a7nAChR)-initiated cholinergic anti-inflammatory pathway and wingless-type mouse mammary tumor virus integration site (Wnt)-related cascades [1, 27] . Phosphorylation of STAT3 at Tyr705 is important for the production of IL-1b and IL-6 in LPS-stimulated innate cells [28] . The inhibition of GSK3b in various cell types upon stimulation with IFNg suppresses STAT3 phosphorylation at Tyr705 [29] . By contrast, GSK3b inhibition enhances the production of IL-10, a prototypic inducer of STAT3 phosphorylation [30] , and leads to the later enhancement of phosphorylation of STAT3. Thus, it will be interesting to determine how these opposing effects of GSK3 inhibition on STAT3 phosphorylation, both by directly suppressing phosphorylation of STAT3 and enhancing STAT3 phosphorylation by augmented IL-10, affect the overall anti-inflammatory property of GSK3 inhibition.
The PI3K-Akt-GSK3b pathway has been demonstrated as an important signaling pathway responsible for the acetylcholine-mediated anti-inflammatory response [27] . The cholinergic anti-inflammatory pathway is activated by the interaction of neuronal or locally derived nonneuronal acetylcholine with a7nAChRs on the surface of immune cells [27, 31] . Classic studies by Tracey and colleagues provided evidence that stimulation of the vagus nerve, and a7nAChRs agonists (acetylcholine and nicotine), prevented cytokine release and pathological sequelae in experimental sepsis, endotoxemia, ischemia/reperfusion injury, hemorrhagic shock, arthritis, and other inflammatory disorders [32] . Activation of a7nAChR by cotinine, a major metabolite of nicotine, leads to activation of PI3K which then phospho-activates Akt, which subsequently phospho-inactivates GSK3b. Cotinine-induced inactivation of GSK3b does not affect the absolute or phosphorylated levels of NF-kB but does increase the levels of the CREB transcription factor and by this route augments the production of anti-inflammatory IL-10 in monocytes stimulated with LPS or other surface-exposed TLR-agonists [27, 33] . Such innate suppression by tobacco alkaloids may be an important clue to the increased susceptibility of smokers to multiple bacterial diseases, including those caused by Mycobacterium tuberculosis, Legionella pneumophila, Moraxella catarrhalis, Neisseria meningitidis, Chlamydia trachomatis, Porphyromonas gingivalis, and Helicobacter pylori, as well as post-surgical and nosocomial infections [34] . Indeed, cotinine, a stable molecule that circulates at approximately tenfold the levels of nicotine, suppresses the innate response to bacterial stimuli at concentrations similar to those exposed to second-hand smoke [27] .
JAK2 (Janus kinase 2)-mediated signaling is also important in the cholinergic anti-inflammatory pathway. JAK2 has been reported to be recruited to a7nAChRs on the surface of macrophages upon cholinergic anti-inflammatory pathway engagement, leading to STAT3 activation and suppression of the innate response [35] . a7nAChR engagement promotes GSK3b phosphorylation and abrogates TLR-induced cytokine production [27] . De Jonge et al. found that activation of JAK2 controls the antiinflammatory potential of nicotinic agonists in macrophages, and thus JAK2 activation may be beneficial in infection control. JAK3 has now been established as a GSK3b-dependent negative regulator of inflammation with suggestions, from JAK3 knockout mice, that JAK3 is key in preventing bacteria-induced intestinal inflammation (neutrophil infiltration, IL-17 expression, and epithelial damage) [36] . Thus, JAK2 and JAK3 may be differentially involved in the regulation of TLR-mediated inflammatory responses.
Wnt-related signaling events have also been shown to play an important role in the control of inflammation. The canonical Wnt (Wnt/b-catenin) pathway involves phosphoinactivation of GSK3b, which abrogates the degradation of b-catenin, promoting cytosolic accumulation and nuclear translocation of b-catenin [37] . b-Catenin stabilization is known to suppress bacteria-induced inflammation, at least in part, due to physical interactions with NF-kB, in a similar manner to IKB (inhibitor of k light polypeptide gene enhancer in B cells) [38] . Wnt3a has been proposed as the prototypic Wnt innate suppressor, partly due to its ability to suppress proinflammatory cytokine production in response to M. tuberculosis [39] .
Furthermore, a7nAChR agonism has also been shown to augment Wnt signaling [40] . 4 between endogenous pathways intended to minimize collateral damage consequential to infection is likely to emerge, increasing the possibility of more sophisticated and specific therapeutic manipulations of the innate response to microbial stimuli.
In summary, GSK3b is essential for the generation of MAMP-induced proinflammatory cytokines. Differential phosphorylation of GSK3b determines the inflammatory activity of this crucial mediator. Ser9 phosphorylation, in particular, suppresses GSK3b and promotes CREB-CBP interactions, and the production of IL-10, over the formation of NFkB-CBP complexes. a7nAChR agonists represent efficient endogenous or exogenous GSK3b inhibitors which may be exploited therapeutically to alter the innate response to bacterial infection.
GSK3b is a promising therapeutic target for the control of bacteria-induced inflammation Although GSK3b is pleiotropic, it is a crucial immune mediator with sufficient unique activities to have made it a much sought-after therapeutic target over the past decade or more. Indeed, GSK3b targeting has been proposed as a potential strategy for the treatment of multiple diseases that are primarily inflammatory or contain an important inflammatory component, including hypertension, diabetes, inflammatory bowel disease, pancreatitis, rhinosinusitis, psoriasis, cirrhosis, hyperoxia-induced lung injury, myocardial and brain ischemia complications, multiple sclerosis, Alzheimer's disease, neural inflammation, cystic fibrosis, and even traumatic spinal cord and brain injuries and inflammatory components underlying cancer progression.
Novel GSK3b inhibitors continue to emerge, such as SB216763, SB-415286, AR-A014418, thiadiazolidinones [e.g., 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8)], Ro3303544, CHIR98014, and GSK-silencing adenovirus. Several established plant-derived dietary components with reported anti-inflammatory properties, particularly the turmeric polyphenol, curcumin, are GSK3b inhibitors [41] . Of course, lithium has long been established as a potent GSK3b inhibitor. Unfortunately, current inhibitors are not as selective as hoped or are not effective in vivo, leading to ongoing efforts to generate new ones that are truly highly selective [42] .
Because GSK3b is a central regulator of the inflammatory response, it has been extensively studied as a therapeutic target for sepsis, the systemic response to bacteria and bacteria-derived toxins, and sepsis-induced multiple organ failure and death. Inhibition of GSK3b was established as a potent downregulator of TLR-mediated inflammatory responses in the seminal paper by Martin et al. [17] . This general phenomenon has been shown to hold true in various specific infections. In an elegant study in 2006, Dugo et al. examined the influence of several GSK3b inhibitors (TDZD-8, SB216763, and SB415286) on LPSor LPS plus peptidoglycan-induced mortality and organspecific (kidney, liver, pancreas and neuromuscular) biomarkers of dysfunction. Each inhibitor effectively attenuated shock-induced organ damage [43] . Recently, Noh et al. have shown that, in LPS-induced toxemia, GSK3 inhibition by SB415286 induces protein kinase Cd (PKCd) and, subsequently, ERK1/2 activation, resulting in increased expression of anti-inflammatory IL-10 and abrogated septic shock [44] .
Pulmonary and cardiac aspects of septic shock have received particular attention. In a murine cecal ligation and puncture sepsis model, glucan phosphate, which attenuates cardiac dysfunction in this system, suppresses sepsis-associated macrophage migration inhibitory factor (MIF) expression and cardiomyocyte apoptosis, concomitantly with activation of the Akt/GSK3b pathway [45] . The manipulation of GSK3b in cardiomyocytes, through the use of SB216763, dominant negative mutants, or adenoviral overexpression, has also been shown to control LPSinduced TNF expression [46] .
Acute respiratory distress syndrome (ARDS), associated with reduced lung surfactants, is the respiratory component of multiple organ failure. Acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a key enzyme in the synthesis of dipalmitoylphosphatidylcholine, an important surfactant. One potential mechanism of ARDS development is that, upon LPS-stimulation, LPCAT1 is phosphorylated by GSK3b, and is then ubiquitinated and targeted for degradation [47] . Inhaled aerosolized insulin, known to inhibit GSK3b, has been proposed as a treatment for sepsis-induced ARDS [48] . In a cecal ligation and puncture sepsis model, LiCl reduced systemic cytokine (IL-1b, IL-6, and TNF) levels. LiCl treatment also reduced pulmonary 8-iso-prostaglandin F2a (8-ISO), increased lung superoxide dismutase (SOD) activity, and resulted in a dose-related reduction in pulmonary inflammation. Therefore, although GSK3b activity itself was not monitored, LiCl -the classic GSK3 antagonist -is a potential treatment for sepsis-induced lung injury [49] .
Muscle loss is a well-established consequence of prolonged sepsis, and LiCl or the thiadiazolidinone derivative TDZD-8 were shown to suppress efficiently sepsis-induced protein breakdown [50] .
The role of GSK3b in bacteria-induced bone pathologies has also been addressed. CD40 is a costimulatory molecule, and interaction of CD40 with CD154 on T helper (Th) cells is required for the activation of antigen-presenting cells, such as dendritic cells and macrophages. It is now established that bacterial infection with several osteopathogens -P. gingivalis, Staphylococcus aureus, and Salmonella enterica -promotes surface expression of CD40 on osteoblasts, and this may then contribute to osteoinflammation by interacting with T cells and the generation of proinflammatory mediators [51] . This enhanced immunological function may well correlate with reduced osteoblastic capacity to lay down new bone matrix. Die et al. have shown that SB216763 suppresses IKBb phosphorylation and decreases the expression of CD40 as well as the production of IL-6, TNF, and IL-1b in P. gingivalis LPS-stimulated murine osteoblast-like cells [51] . Thus, GSK3b was identified as a potential therapeutic target for infection-induced bone loss. To this end, Adamowicz et al. have recently employed the GSK3b-inhibitor, SB216763, to abrogate completely P. gingivaliselicited alveolar bone loss in a murine model of periodontitis [16] (Figure 3) . P. gingivalis has also been associated with multiple chronic, systemic conditions. In a recent study examining P. gingivalis and diabetes, it has been shown that this pathogen translocates from the oral cavity to the liver, infects hepatic cells, and decreases glycogen synthesis in a manner likely to be driven by an insulin receptor substrate-1(IRS-1)-Akt-GSK3b signaling cascade [52] .
Inhibition of GSK3b has been shown to reduce inflammation and mortality in other infectious disease models [53] [54] [55] . In meningitis studies, GSK3b inhibition (by SB216763 or LiCl) has been shown to suppress LPSinduced proinflammatory cytokines and promote IL-10 secretion in rat mixed glia-enriched cortical cultures [56] . Moreover, the anesthetic agent, propofol, suppresses LPS-induced proinflammatory cytokine production in LPS-stimulated BV2 microglia cells in a manner that could involve both TLR4 downregulation and the inactivation of GSK3b [54] . Microglia are producers of large concentrations of shock-inducing cytokines and others have confirmed that GSK3b inhibition upregulates IL-10 in BV2 cells as well as suppressing iNOS [57] . Most recently, it has been shown that the anti-inflammatory properties of lipoic acid on LPS-stimulated BV2 cells are mediated through GSK3b inactivation [52] . Furthermore, active (unphosphorylated) GSK3b is important for adhesion molecule activation, endothelial interaction, and monocyte crossing of the blood-brain barrier in response to bacteria and other inflammatory stimuli [58] .
Heat-inactivated S. aureus induces TNF and NO production in microglia, and the production of both inflammatory mediators is abrogated by GSK3b inhibition by LiCl or 6-bromo-indirubin-3 0 -oxime [59] . IL-10 is considered to be particularly important in protecting against S. aureus-mediated brain abscesses and is augmented by GSK3b inhibition [59] . Francisella tularensis induces proinflammatory cytokine production by increasing GSK3b activity. GSK3b is an attractive target for the treatment of tularemia because LiCl suppresses inflammatory mediators (IL-6, IL-12p40, and TNF) induced by F. tularensis upon infection of macrophages, and promotes survival of F. tularensis-infected mice [55] .
In addition to a role in controlling acute inflammatory responses to bacterial infection, GSK3b can also contribute to long-term vaccine responses. Age-related immune senescence can reduce the efficacy of antibacterial vaccines, including the pneumococcal polysaccharide vaccine. It has been established that, in aged animals stimulated with Streptococcus pneumoniae, the innate response is suppressed. In spleen-derived rat macrophages, this was associated with altered PI3K-Akt-GSK3b signal pathway activity and characterized by a reduced proinflammatory cytokine profile and elevated IL-10. Furthermore, inhibition of PI3K restored an appropriate innate response to S. pneumoniae, as did TLR1/2-, TLR2/6-, and TLR4-specific agonists [60] . The distance from the cementoenamel junction (CEJ) to the alveolar bone crest (ABC) was measured 6 weeks postinfection at 14 predetermined maxillary buccal sites (marked by yellow diamonds) in the same three control and two experimental groups. Data are presented as mean distance CEJ-ABC in mm AESD. Symbols: *, p<0.05 compared to the P. gingivalis-treated group; **, p<0.01 compared to the P. gingivalis-treated group. Reproduced, with permission, from Adamowicz et al. [16] .
Trends in Microbiology April 2014, Vol. 22, No. 4 GSK3b is thus a potentially effective therapeutic target for bacterial shock-induced organ damage, ARDS, bone diseases, meningitis, and tularemia. The development of more potent and specific GSK3b inhibitors, alongside deeper understandings of GSK3b-related signaling events, could lead to a new paradigm of treatment for bacterial diseases -one that aims prevents to prevent the multiple pathological consequences of robust inflammation, and which is likely to be employed in conjunction with contemporary antibacterial regimens.
Exploitation of GSK3b and related molecules by pathogenic bacteria Bacteria are known to circumvent aspects of the immune response by dysregulating kinase networks, as reviewed by Krachler et al. [61] . For example, the Shigella phosphothreonine lyase, OspF, inhibits ERK and, consequently, suppresses inflammation [61] ; the Yersinia spp. acetyltransferase, YopJ, inhibits MAPK, influencing apoptosis [61, 62] ; Pseudomonas aeruginosa ExoS and ExoT differentially influence Rac1 GTPase activity and strongly influence innate cell specific invasion [63] ; whereas the nucleosidediphosphate-kinase, NDK, of P. gingivalis blocks ATPinduced reactive oxygen species (ROS) production in innate cells [64] , and the serine phosphatase, SerB, dephosphorylates the p65 NF-kB subunit [65] . Thus, targeting of immune signaling molecules by bacteria is an established phenomenon. Although it has long been known that multiple viruses, including adenoviruses and influenza viruses, specifically interfere with the PI3K-Akt-GSK3b axis to promote replication [66] , increasing evidence suggests that one mechanism of immune evasion by bacterial pathogens is also to target GSK3b-related signaling events.
The phosphoinositide phosphatase, SigD (SopB), of S. enterica phosphorylates Akt and, subsequently, GSK3b and FoxO3a -a process thought to be important in the invasion of enterocytes [67] . P. aeruginosa takes advantage of PI3K signaling to invade epithelial cells basolaterally. PI3K activation by P. aeruginosa results in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) generation, Akt recruitment, and the generation of PIP3-rich membrane regions, thereby facilitating bacterial entry [68] . The role of the downstream regulator, GSK3b, in this invasion system has not been directly addressed. A similar requirement for PI3K in host cell invasion has been identified for other pathogens, including group A streptococci [69] , Helicobacter pylori [70] , Chlamydia pneumoniae [71] and Listeria monocytogenes [72] .
Targeting GSK3b appears to increase the virulence of some pathogens. Bacillus anthracis influences GSK3b phosphorylation in pulmonary epithelial cells, and both the lethal (LeTx, a MAPK inhibitor) and edema toxins (EdTx, an adenylate cyclase) produced by this bacterium inhibit AKT phosphorylation. Furthermore, the delivery of wortmannin, a PI3K-AKT inhibitor, hastens death in toxin-producing B. anthracis-infected mice [73] . S. aureus similarly exploits GSK3b for virulence, with PI3K-AKTmediated GSK3b phosphorylation at Ser9 being a key event during endothelial invasion [74] .
Early in macrophage infection, Yersinia enterocolitica phosphorylates GSK3b, along with Akt and FKHRL1, in a PI3K-dependent manner, and these phosphorylation events are reversed later by virulent -but not avirulent -strains. These events are mediated by the Y. enterocolitica YopH protein. It has been hypothesized that one key consequence of such YopH activity is immunoprotection via the downregulation of MCP-1 and the subsequent inhibition of pathogen recruitment to lymph nodes [75] . YopH also inhibited T cell proliferation and the PI3K-dependent secretion of IL-2 [75] .
Group B streptococci are important etiological agents of pneumonia, sepsis, and -particularly in newbornsmeningitis. Because epithelial infection by Salmonella enterica serovar Typhimurium (S. Typhimurium) leads to bacterial SopB-mediated activation of Akt and suppression of caspase 3-induced apoptosis [76] , Burnham et al. examined the importance of GSK3b in group B streptococcal infection, and found that infection-elicited GSK3b phosphorylation protected against camptothecin-induced epithelial apoptosis for at least 18 h [77] . Presumably, this is a mechanism that promotes bacterial persistence inside target eukaryotic cells. Inhibitors of the Akt-GSK3b signaling cascade, which is also important in actin dynamics, have been used to block effectively bacterial invasion of, but not attachment to, epithelial cells [77] . Similar data have been found with group A streptococci [53] .
Direct or indirect inactivation of GSK3b by bacteria presumably suppresses the innate response, thereby providing immune protection to the infecting microbe. Indeed, non-typeable Haemophilus influenza has been shown to activate the PI3K-Akt pathway in epithelial cells, leading to p38 MAP kinase inhibition and downregulation of TLR2 [78] . S. Typhimurium infection leads to reduced phosphorylation, and thus enhanced activity, of GSK3b and degradation of b-catenin, thus augmenting the production of proinflammatory cytokines IL-6 and IL-8 and colonic inflammation [38] .
Virulent strains of H. pylori, that are associated with gastric ulcers and cancer, secrete high amounts of vacuolating toxin, VacA -a promising H. pylori vaccine component. VacA, which exerts an influence on multiple eukaryotic signaling events, inactivates GSK3b in a PI3K-dependent manner [79, 80] . H. pylori isolates from subjects exhibiting regression of gastric intestinal metaplasia following H. pylori eradication, more efficiently phosphorylate GSK3b in gastric adenocarcinoma (AGS) cells than do strains from patients with persistent intestinal metaplasia [81] . Furthermore, the Chlamydomonas-derived peptide, H-P-6 (Pro-Gln-Pro-Lys-Val-LeuAsp-Ser), has been shown to suppress H. pylori-induced hyperproliferation and migration of AGS cells by a mechanism that involves epidermal growth factor receptor (EGFR) activation of the PI3K-Akt pathway and GSK3b inactivation [82] . Thus, GSK3b represents a potential therapeutic target for the prevention of H. pylori-driven gastric cancer.
In mice, pulmonary infection with Klebsiella pneumonia also leads to GSK3b phosphorylation, together with multiple other effects on eukaryotic kinases, that may well be relevant to immune suppression and avoidance [83] .
Finally, there may be scope to exploit bacterial GSKtargeting products therapeutically. For example, the Streptomyces albus-derived livestock antibiotic, salinomycin, that is being developed as an anticancer drug, clearly phosphorylates Akt, GSK3b, and mammalian target of rapamycin (mTOR) in head and neck squamous cell carcinoma stem cells [84] . In a similar vein, S632A3, a new glutarimide antibiotic isolated from Streptomyces hygroscopicus, is a potent inhibitor of inflammation in LPSstimulated macrophage-like RAW cells. This inflammatory suppression occurs via inactivation of GSK3b and the differential promotion of CREB-CBP interactions over NF-kB which, subsequently, leads to increased IL-10 production [85] . Several other antibiotics have also been shown to influence GSK3b activity [86] . There may also be occasion to employ GSK3b inhibitors as an adjunct to antibiotic treatment. Streptomyces verticillus-derived bleomycin, used in the treatment of various cancers, can induce lung injury. In a murine model, bleomycin-induced pulmonary inflammation, characterized by neutrophil infiltration, edema, and the accumulation of inflammatory mediators (myeloperoxidase, iNOS, TNF and IL-1b), is dramatically reduced upon GSK3b inhibition by TDZD8 [87] .
We are beginning to understand that several bacteria exploit GSK3b and related signaling molecules to subvert the immune response. It is not yet clear whether or not this is a widespread strategy among human pathogens. Furthermore, the molecular mechanisms of GSK3b targeting by microbes remain to be elucidated more fully. Understanding such pathogen-GSK3b interactions could lead to novel antibacterial therapeutics.
Concluding remarks
GSK3b plays a crucial role in the regulation of pathogeninduced inflammatory responses through the regulation of pro-and anti-inflammatory cytokine production. GSK3b has also been aggressively pursued as a therapeutic target for the control of infectious diseases. Furthermore, GSK3b is exploited by pathogenic bacteria seeking to avoid the immune system. Further molecular understanding of complex GSK3b signaling events (Box 1), combined with the emergence of better and more-specific inhibitors, is likely to lead to more effective interventions.
Box 1. Outstanding questions
Can more specific, pharmacologically desirable GSK3b inhibitors be developed? What pro-and anti-inflammatory signaling pathways crosstalk with GSK3b? Will conjunctive antibacterial (antibiotics) and anti-inflammatory (GSK3b) therapies prove more efficacious against shock than individual therapies? Is targeting of GSK3b a common immune evasion strategy of pathogenic bacteria?
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